[go: up one dir, main page]

HK1242185B - 用於治疗实体瘤的epha3抗体 - Google Patents

用於治疗实体瘤的epha3抗体

Info

Publication number
HK1242185B
HK1242185B HK18101531.4A HK18101531A HK1242185B HK 1242185 B HK1242185 B HK 1242185B HK 18101531 A HK18101531 A HK 18101531A HK 1242185 B HK1242185 B HK 1242185B
Authority
HK
Hong Kong
Prior art keywords
antibody
epha3
sequence
tumor
region
Prior art date
Application number
HK18101531.4A
Other languages
German (de)
English (en)
French (fr)
Other versions
HK1242185A1 (zh
Inventor
Martin Lackmann
Andrew Mark Scott
Christopher R Bebbington
Geoffrey T Yarranton
Catherine To
Carmelina Murone
Original Assignee
Humanigen, Inc.
Monash University
Ludwig Institute For Cancer Research Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humanigen, Inc., Monash University, Ludwig Institute For Cancer Research Limited filed Critical Humanigen, Inc.
Publication of HK1242185A1 publication Critical patent/HK1242185A1/zh
Publication of HK1242185B publication Critical patent/HK1242185B/zh

Links

HK18101531.4A 2007-03-08 2018-01-31 用於治疗实体瘤的epha3抗体 HK1242185B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US893848P 2007-03-08

Publications (2)

Publication Number Publication Date
HK1242185A1 HK1242185A1 (zh) 2018-06-22
HK1242185B true HK1242185B (zh) 2022-06-10

Family

ID=

Similar Documents

Publication Publication Date Title
EP3199180B1 (en) Epha3 antibodies for the treatment of solid tumors
JP5876728B2 (ja) ＥｐｈＡ３に対する抗体を用いた、白血病および慢性骨髄増殖性疾患の治療方法
US20190270821A1 (en) Epha3 antibodies for the treatment of pulmonary fibrosis
CA2687575A1 (en) Humanized and chimeric anti-cd59 antibodies that mediate cancer cell cytotoxicity
AU2011235867B2 (en) EphA3 antibodies for the treatment of multiple myeloma
HK1242185B (zh) 用於治疗实体瘤的epha3抗体
HK1242185A1 (zh) 用於治療實體瘤的epha3抗體
US9109032B2 (en) Methods of treating hematological proliferative disorders by targeting EphA3 expressed on aberrant vasculature in bone marrow